BACKGROUND: Despite radical surgical and chemotherapeutic treatment of ovarian cancer, the majority of patients develop recurrent disease. Secondary cytoreductive surgery can result in favourable outcome in selected patients, but information regarding feasibility, safety and perioperative outcome of these often complex procedures is limited. METHODS: Surgical parameters in patients with recurrent epithelial ovarian cancer selected for secondary cytoreduction were analysed and compared to patients undergoing primary cytoreduction. RESULTS: In total, 222 patients undergoing radical cytoreduction were analysed (48 patients for relapsed disease and 174 patients at primary diagnosis of advanced ovarian cancer). The range of surgical procedures was similar in both groups. In 48% of secondary cytoreductions 'optimal surgical results' (residual tumour <1 cm) were obtained and 33% of the patients had no residual disease compared to 82% and 58% at primary cytoreduction. There was no significant difference in perioperative complication rates. The duration of surgery was shorter and the number of transfused blood products was smaller at secondary cytoreduction (p < 0.001 and p = 0.001). CONCLUSION: Secondary cytoreduction in relapsed ovarian cancer is safe and feasible and perioperative outcome is not inferior compared to primary cytoreduction. Surgery-associated morbidity should represent a minor aspect in the selection and counselling of patients regarding treatment options for recurrent ovarian cancer.
BACKGROUND: Despite radical surgical and chemotherapeutic treatment of ovarian cancer, the majority of patients develop recurrent disease. Secondary cytoreductive surgery can result in favourable outcome in selected patients, but information regarding feasibility, safety and perioperative outcome of these often complex procedures is limited. METHODS: Surgical parameters in patients with recurrent epithelial ovarian cancer selected for secondary cytoreduction were analysed and compared to patients undergoing primary cytoreduction. RESULTS: In total, 222 patients undergoing radical cytoreduction were analysed (48 patients for relapsed disease and 174 patients at primary diagnosis of advanced ovarian cancer). The range of surgical procedures was similar in both groups. In 48% of secondary cytoreductions 'optimal surgical results' (residual tumour <1 cm) were obtained and 33% of the patients had no residual disease compared to 82% and 58% at primary cytoreduction. There was no significant difference in perioperative complication rates. The duration of surgery was shorter and the number of transfused blood products was smaller at secondary cytoreduction (p < 0.001 and p = 0.001). CONCLUSION: Secondary cytoreduction in relapsed ovarian cancer is safe and feasible and perioperative outcome is not inferior compared to primary cytoreduction. Surgery-associated morbidity should represent a minor aspect in the selection and counselling of patients regarding treatment options for recurrent ovarian cancer.
Authors: Joanne O'Dwyer; Roisin E O'Cearbhaill; Robert Wylie; Saoirse O'Mahony; Michael O'Dwyer; Garry P Duffy; Eimear B Dolan Journal: Adv Ther (Weinh) Date: 2020-08-16
Authors: F Trillsch; S Mahner; E Vettorazzi; L Woelber; A Reuss; K Baumann; M-D Keyver-Paik; U Canzler; K Wollschlaeger; D Forner; J Pfisterer; W Schroeder; K Muenstedt; B Richter; C Fotopoulou; B Schmalfeldt; A Burges; N Ewald-Riegler; N de Gregorio; F Hilpert; T Fehm; W Meier; P Hillemanns; L Hanker; A Hasenburg; H-G Strauss; M Hellriegel; P Wimberger; S Kommoss; F Kommoss; S Hauptmann; A du Bois Journal: Br J Cancer Date: 2015-01-06 Impact factor: 7.640
Authors: Fabian Trillsch; Jan David Ruetzel; Uwe Herwig; Ulrike Doerste; Linn Woelber; Donata Grimm; Matthias Choschzick; Fritz Jaenicke; Sven Mahner Journal: J Ovarian Res Date: 2013-07-09 Impact factor: 4.234
Authors: Rafli van de Laar; Petra L M Zusterzeel; Toon Van Gorp; Marrije R Buist; Willemien J van Driel; Katja N Gaarenstroom; Henriette J G Arts; Johannes C M van Huisseling; Ralph H M Hermans; Johanna M A Pijnenborg; Eltjo M J Schutter; Harold M P Pelikan; Jos H A Vollebergh; Mirjam J A Engelen; Joanna Inthout; Roy F P M Kruitwagen; Leon F A G Massuger Journal: BMC Cancer Date: 2014-01-14 Impact factor: 4.430